Pluri Inc. Interest Expense Nonoperating
Pluri Inc. (PLUR) reported Interest Expense Nonoperating of $932.00 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-10.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-09-10
- Pluri Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $235.00K, a 0.86% increase year-over-year.
- Pluri Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $237.00K, a 11.79% increase year-over-year.
- Pluri Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $231.00K, a 9.48% increase year-over-year.
- Pluri Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $229.00K, a 5.53% increase year-over-year.
- Pluri Inc. interest expense nonoperating for fiscal 2026 was $932.00K, a 6.76% increase from fiscal 2025.
- Pluri Inc. interest expense nonoperating for fiscal 2025 was $873.00K, a 0.81% increase from fiscal 2024.
- Pluri Inc. interest expense nonoperating for fiscal 2024 was $866.00K, a 2.73% increase from fiscal 2023.
- Pluri Inc. interest expense nonoperating for fiscal 2023 was $843.00K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $235.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-10 | $472.00K derived: sum of 2 quarters · filed 2026-09-10 | $703.00K derived: sum of 3 quarters · filed 2026-09-10 | $932.00K 10-K · filed 2026-09-10 |
| 2026-03-31 | $237.00K 10-Q · filed 2026-05-14 | $468.00K derived: sum of 2 quarters · filed 2026-05-14 | $697.00K 10-Q · filed 2026-05-14 | $930.00K derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-12-31 | $231.00K 10-Q · filed 2026-02-12 | $460.00K 10-Q · filed 2026-02-12 | $693.00K derived: sum of 3 quarters · filed 2026-09-10 | $905.00K derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-09-30 | $229.00K 10-Q · filed 2025-11-12 | $462.00K derived: sum of 2 quarters · filed 2026-09-10 | $674.00K derived: sum of 3 quarters · filed 2026-09-10 | $885.00K derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-06-30 | $233.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-10 | $445.00K derived: sum of 2 quarters · filed 2026-09-10 | $656.00K derived: sum of 3 quarters · filed 2026-09-10 | $873.00K 10-K · filed 2026-09-10 |
| 2025-03-31 | $212.00K 10-Q · filed 2026-05-14 | $423.00K derived: sum of 2 quarters · filed 2026-05-14 | $640.00K 10-Q · filed 2026-05-14 | $858.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $211.00K 10-Q · filed 2026-02-12 | $428.00K 10-Q · filed 2026-02-12 | $646.00K derived: sum of 3 quarters · filed 2026-02-12 | $864.00K derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-09-30 | $217.00K 10-Q · filed 2025-11-12 | $435.00K derived: sum of 2 quarters · filed 2025-11-12 | $653.00K derived: sum of 3 quarters · filed 2025-11-12 | $869.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $218.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-17 | $436.00K derived: sum of 2 quarters · filed 2025-09-17 | $652.00K derived: sum of 3 quarters · filed 2025-09-17 | $866.00K 10-K · filed 2025-09-17 |
| 2024-03-31 | $218.00K 10-Q · filed 2025-05-13 | $434.00K derived: sum of 2 quarters · filed 2025-05-13 | $648.00K 10-Q · filed 2025-05-13 | |
| 2023-12-31 | $216.00K 10-Q · filed 2025-02-11 | $430.00K 10-Q · filed 2025-02-11 | ||
| 2023-09-30 | $214.00K 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | $843.00K 10-K · filed 2024-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |